Insider Transactions Reported by 12 Insiders of INFINITY PHARMACEUTICALS, INC.

Location: Cambridge, MA

Quick Takeaways

INFINITY PHARMACEUTICALS, INC. has 12 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are not currently available.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 19 May 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

INFINITY PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Adelene Q. Perkins	Director	$83,421	Mixed	08 Sep 2023
Anthony B. Evnin	Director	$15,078	Mixed	16 Jun 2022
Stephane Peluso	Chief Scientific Officer	$2,594	Mixed	02 Aug 2022
Brian Schwartz	Director	$2,164	Mixed	16 Jun 2022
Richard Gaynor	Director		Mixed	16 Jun 2022
Norman C. Selby	Director		Mixed	16 Jun 2022
Robert Ilaria Jr.	Chief Medical Officer		Mixed	11 Jan 2022
Seth A. Tasker	Chief Business Officer		Mixed	11 Jan 2022
David W. Beier	Director		Mixed	16 Jun 2022
Lawrence E. Bloch	President		Mixed	11 Jan 2022
Sujay Kango	Director		Mixed	30 Mar 2022
Samuel Agresta	Director		Mixed	16 Jun 2022

Top shareholders of INFINITY PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Adelene Q. Perkins	3/4/5	Director	— class O/S missing	1,191,738	$83,421	—	08 Sep 2023	3/4/5
Anthony B. Evnin	3/4/5	Director	— mixed-class rows	260,403 mixed-class rows	$15,078	—	16 Jun 2022	3/4/5
Stephane Peluso	3/4/5	Chief Scientific Officer	— class O/S missing	37,052	$2,594	—	02 Aug 2022	3/4/5
Brian Schwartz	3/4/5	Director	— mixed-class rows	75,919 mixed-class rows	$2,164	—	16 Jun 2022	3/4/5
Lawrence E. Bloch	3/4/5	President	— class O/S missing	335,000	—	—	11 Jan 2022	3/4/5
Seth A. Tasker	3/4/5	Chief Business Officer	— class O/S missing	225,000	—	—	11 Jan 2022	3/4/5
Sujay Kango	3/4/5	Director	— class O/S missing	90,000	—	—	30 Mar 2022	3/4/5
Robert Ilaria Jr.	3/4/5	Chief Medical Officer	— class O/S missing	87,472	—	—	11 Jan 2022	3/4/5
David W. Beier	3/4/5	Director	— class O/S missing	45,000	—	—	16 Jun 2022	3/4/5
Richard Gaynor	3/4/5	Director	— class O/S missing	45,000	—	—	16 Jun 2022	3/4/5
Samuel Agresta	3/4/5	Director	— class O/S missing	45,000	—	—	16 Jun 2022	3/4/5
Norman C. Selby	3/4/5	Director	— class O/S missing	10,000	—	—	16 Jun 2022	3/4/5

Recent Insider Transactions by Companies or Individuals for INFINITY PHARMACEUTICALS, INC.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.